ES2875899T3 - Compuestos inhibidores de autotaxina - Google Patents

Compuestos inhibidores de autotaxina Download PDF

Info

Publication number
ES2875899T3
ES2875899T3 ES14864293T ES14864293T ES2875899T3 ES 2875899 T3 ES2875899 T3 ES 2875899T3 ES 14864293 T ES14864293 T ES 14864293T ES 14864293 T ES14864293 T ES 14864293T ES 2875899 T3 ES2875899 T3 ES 2875899T3
Authority
ES
Spain
Prior art keywords
compound
thio
acid
fluoro
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14864293T
Other languages
English (en)
Spanish (es)
Inventor
John Hutchinson
David Lonergan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sabre Therapeutics LLC
Original Assignee
Sabre Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sabre Therapeutics LLC filed Critical Sabre Therapeutics LLC
Application granted granted Critical
Publication of ES2875899T3 publication Critical patent/ES2875899T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES14864293T 2013-11-22 2014-11-20 Compuestos inhibidores de autotaxina Active ES2875899T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907965P 2013-11-22 2013-11-22
US201462038121P 2014-08-15 2014-08-15
PCT/US2014/066706 WO2015077503A1 (en) 2013-11-22 2014-11-20 Autotaxin inhibitor compounds

Publications (1)

Publication Number Publication Date
ES2875899T3 true ES2875899T3 (es) 2021-11-11

Family

ID=53180152

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14864293T Active ES2875899T3 (es) 2013-11-22 2014-11-20 Compuestos inhibidores de autotaxina

Country Status (31)

Country Link
US (7) US9334261B2 (enExample)
EP (2) EP3878848A1 (enExample)
JP (1) JP6501367B2 (enExample)
KR (2) KR102515248B1 (enExample)
CN (2) CN105793253B (enExample)
AU (2) AU2014352888B2 (enExample)
BR (1) BR112016010220B1 (enExample)
CA (1) CA2930737C (enExample)
CL (1) CL2016001231A1 (enExample)
CR (2) CR20190394A (enExample)
CY (1) CY1124407T1 (enExample)
DK (1) DK3071561T3 (enExample)
EA (1) EA030068B1 (enExample)
ES (1) ES2875899T3 (enExample)
HR (1) HRP20210957T1 (enExample)
HU (1) HUE055213T2 (enExample)
IL (2) IL245383B (enExample)
LT (1) LT3071561T (enExample)
MX (2) MX375706B (enExample)
MY (1) MY182095A (enExample)
NI (1) NI201600071A (enExample)
NZ (1) NZ720478A (enExample)
PE (1) PE20160654A1 (enExample)
PH (1) PH12016500862B1 (enExample)
PL (1) PL3071561T3 (enExample)
PT (1) PT3071561T (enExample)
RS (1) RS62027B1 (enExample)
SI (1) SI3071561T1 (enExample)
SM (1) SMT202100531T1 (enExample)
WO (1) WO2015077503A1 (enExample)
ZA (2) ZA201603083B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
EP3046909A4 (en) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
CA2930735A1 (en) 2013-11-22 2015-05-28 Sabre Therapeutics Llc Tetracyclic autotaxin inhibitors
PE20160654A1 (es) 2013-11-22 2016-07-15 Pharmakea Inc Compuestos de inhibidor de autotaxina
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN116059203A (zh) 2015-05-27 2023-05-05 赛博治疗有限责任公司 自分泌运动因子抑制剂及其用途
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
US11000142B2 (en) 2016-12-06 2021-05-11 John Joseph Girard Flexible floor mat incorporating LED lighting
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
MX2020002241A (es) 2017-08-28 2020-09-03 Angiex Inc Anticuerpos anti-tm4sf y métodos de uso de los mismos.
MX2021010254A (es) 2019-02-27 2021-09-21 Angiex Inc Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
AU2023265017A1 (en) * 2022-05-03 2024-12-12 Df 2024 Ip Acquisition, Llc Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat
CN116239577A (zh) * 2023-03-27 2023-06-09 沈阳药科大学 一种制备Cudetaxestat的方法
CN116396205B (zh) * 2023-04-20 2024-10-01 沈阳药科大学 一种n-芳基吲哚衍生物及其制备方法和应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210574A (en) 1991-03-08 1993-05-11 Mita Industrial Co., Ltd. Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum
US5186522A (en) 1991-09-24 1993-02-16 Midland Brake, Inc. Air dryer purge line
DE69316741T2 (de) 1992-11-10 1998-09-10 Caterpillar Inc Magnetventil
US5407368A (en) 1992-12-15 1995-04-18 Minnesota Mining And Manufacturing Company Electrode connector
US5761473A (en) 1993-01-08 1998-06-02 International Business Machines Corporation Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking
US5564949A (en) 1995-01-05 1996-10-15 Thomas & Betts Corporation Shielded compact data connector
JP2664048B2 (ja) 1995-03-27 1997-10-15 科学技術庁金属材料技術研究所長 六フッ化二ケイ素の合成法
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
AU2002213421A1 (en) 2000-10-03 2002-04-15 Lilly Icos Llc Condensed pyridoindole derivatives
BR0208790A (pt) 2001-04-11 2004-03-30 Idenix Cayman Ltd Fenilindoìs para o tratamento de hiv
DE60203529T2 (de) 2001-09-27 2006-03-16 F. Hoffmann-La Roche Ag Indolderivate als cox-ii-inhibitoren
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
WO2004019869A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2495943C (en) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
AU2004240649A1 (en) 2003-05-19 2004-12-02 Irm, Llc Immunosuppressant compounds and compositions
EP1701940B1 (en) 2003-12-23 2008-05-28 H.Lundbeck A/S 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
WO2005111278A1 (ja) 2004-05-19 2005-11-24 Sumitomo Electric Industries, Ltd. Ｉｉｉ族窒化物半導体結晶およびその製造方法ならびにｉｉｉ族窒化物半導体デバイス
KR101141650B1 (ko) 2004-09-30 2012-05-17 엘지전자 주식회사 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20060270634A1 (en) 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
AR054394A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
WO2007041600A2 (en) 2005-10-03 2007-04-12 Luminescent Technologies, Inc. Mask-pattern determination using topology types
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
WO2008157361A1 (en) 2007-06-15 2008-12-24 University Of Utah Research Foundation α-CHLORO AND α-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047738A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
US8268891B1 (en) 2007-11-13 2012-09-18 University Of Memphis Research Foundation Autotaxin inhibitors
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
US20110110886A1 (en) 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
WO2010040080A1 (en) 2008-10-03 2010-04-08 Abby Louise Parrill-Baker Mechanism-based inactivators of autotaxin
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
US8530650B2 (en) 2008-12-01 2013-09-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer
JP5767205B2 (ja) * 2009-04-02 2015-08-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ オートタキシン阻害剤としての複素環式化合物
US8329907B2 (en) 2009-04-02 2012-12-11 Merck Patent Gmbh Autotaxin inhibitors
AU2010234087B2 (en) 2009-04-02 2016-05-12 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
CA2763016C (en) 2009-05-20 2018-04-17 Eth Zurich Targeting micrornas for metabolic disorders
WO2011002918A1 (en) 2009-06-30 2011-01-06 The University Of Memphis Research Foundation Novel diverse lead compound autotaxin inhibitors
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2011049433A1 (en) 2009-10-23 2011-04-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnosis and treatment of pruritis
WO2011053597A1 (en) 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2011116867A1 (de) * 2010-03-26 2011-09-29 Merck Patent Gmbh Benzonaphthyridinamine als autotaxin-inhibitoren
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
US8673882B2 (en) 2011-01-20 2014-03-18 University Of Tennessee Research Foundation Inhibitors of autotaxin
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
CA2829045A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012123938A1 (en) 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
GB2494154B (en) 2011-08-31 2017-11-29 Metaswitch Networks Ltd Conditional telecommunications
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
EP3243815B1 (en) 2011-10-28 2019-07-10 Inhibitaxin Limited Pyridazine derivatives useful in therapy
JP2013129632A (ja) 2011-12-22 2013-07-04 Ono Pharmaceut Co Ltd Ｅｎｐｐ２阻害化合物
US20130270634A1 (en) 2012-04-12 2013-10-17 Richtek Technology Corporation High voltage device and manufacturing method thereof
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
EP2935249B1 (en) 2012-12-19 2018-12-12 Novartis AG Autotaxin inhibitors
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
TWI499591B (zh) 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
EP3046909A4 (en) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
HRP20181290T1 (hr) 2013-11-05 2018-10-19 Bayer Cropscience Aktiengesellschaft Novi spojevi za suzbijanje člankonožaca
CA2930735A1 (en) 2013-11-22 2015-05-28 Sabre Therapeutics Llc Tetracyclic autotaxin inhibitors
EA201600403A1 (ru) 2013-11-22 2016-10-31 Басф Се N-ацилиминогетероциклические соединения
PE20160654A1 (es) 2013-11-22 2016-07-15 Pharmakea Inc Compuestos de inhibidor de autotaxina
CL2016001118A1 (es) 2013-11-22 2016-12-02 Basf Se Compuestos heterocíclicos de n-acilimino
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CN116059203A (zh) 2015-05-27 2023-05-05 赛博治疗有限责任公司 自分泌运动因子抑制剂及其用途

Also Published As

Publication number Publication date
SMT202100531T1 (it) 2021-11-12
IL245383B (en) 2019-11-28
PT3071561T (pt) 2021-06-25
HRP20210957T1 (hr) 2021-09-17
ZA202005029B (en) 2022-02-23
CA2930737C (en) 2023-02-21
JP6501367B2 (ja) 2019-04-17
PL3071561T3 (pl) 2021-11-08
EP3071561B1 (en) 2021-03-24
US20160046614A1 (en) 2016-02-18
CN105793253B (zh) 2019-08-23
US20180243267A1 (en) 2018-08-30
US20220265608A1 (en) 2022-08-25
HUE055213T2 (hu) 2021-11-29
US9468628B2 (en) 2016-10-18
WO2015077503A1 (en) 2015-05-28
EA030068B1 (ru) 2018-06-29
US9999615B2 (en) 2018-06-19
ZA201603083B (en) 2022-03-30
EP3071561A1 (en) 2016-09-28
US20160374991A1 (en) 2016-12-29
CR20160289A (es) 2016-09-27
LT3071561T (lt) 2021-08-25
US12268668B2 (en) 2025-04-08
AU2019213425B2 (en) 2021-01-07
CN110372671A (zh) 2019-10-25
US10688081B2 (en) 2020-06-23
AU2014352888A1 (en) 2016-06-09
CL2016001231A1 (es) 2017-01-20
HK1226075A1 (zh) 2017-09-22
EP3071561A4 (en) 2017-04-12
US20240189281A1 (en) 2024-06-13
US11344533B2 (en) 2022-05-31
MX2020009780A (es) 2020-10-12
EP3878848A1 (en) 2021-09-15
MX2016006623A (es) 2017-03-10
CA2930737A1 (en) 2015-05-28
US20160235713A1 (en) 2016-08-18
JP2016537389A (ja) 2016-12-01
KR102515248B1 (ko) 2023-03-29
RS62027B1 (sr) 2021-07-30
IL270168B (en) 2022-02-01
KR20220027276A (ko) 2022-03-07
CY1124407T1 (el) 2022-07-22
EA201690881A1 (ru) 2016-12-30
DK3071561T3 (da) 2021-06-21
AU2014352888B2 (en) 2019-05-09
PH12016500862A1 (en) 2016-07-18
US9334261B2 (en) 2016-05-10
BR112016010220A2 (pt) 2018-05-02
IL245383A0 (en) 2016-06-30
PH12016500862B1 (en) 2020-12-09
CN105793253A (zh) 2016-07-20
CR20190394A (es) 2019-10-29
SI3071561T1 (sl) 2021-11-30
WO2015077503A8 (en) 2015-07-16
AU2019213425A1 (en) 2019-08-29
NZ720478A (en) 2022-02-25
US11779568B2 (en) 2023-10-10
BR112016010220B1 (pt) 2023-05-09
NI201600071A (es) 2016-09-21
KR102367876B1 (ko) 2022-02-24
KR20160079082A (ko) 2016-07-05
MX375706B (es) 2025-03-06
PE20160654A1 (es) 2016-07-15
CN110372671B (zh) 2023-02-21
MY182095A (en) 2021-01-18
US20200268713A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
AU2019213425B2 (en) Autotaxin inhibitor compounds
ES2872553T3 (es) Inhibidores de lisil oxidasa tipo-2 y usos de los mismos
JP6905530B2 (ja) ファルネソイドｘ受容体アゴニストとその使用
ES2900815T3 (es) Compuestos y métodos para inducir la condrogénesis
ES2880766T3 (es) Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
BR112013004750B1 (pt) Derivados de quinolina e quinoxalina como inibidores da cinase
KR20060015283A (ko) 신규한 피리도피라진 및 키나제 억제제로서의 이의 용도
JP2013536200A (ja) オートタキシン阻害剤およびその使用
ES2889100T3 (es) Métodos de uso de los derivados de benzotriazol trisustituidos como inhibidores de dihidroorotato oxigenasa
KR100747106B1 (ko) 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체
HK40012668A (en) Autotaxin inhibitor compounds
HK40012668B (en) Autotaxin inhibitor compounds
HK1226075B (en) Autotaxin inhibitor compounds